Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled, double-blind trial

noticia |

Paulsen Ø., Klepstad P., Rosland J.H., Aass N., Albert E., Fayers P., Kaasa S.

Journal of Clinical Oncology 2014 32:29 (3221-3228)

Results: A total of 592 patients were screened; 50 were randomly assigned, and 47 were analyzed. Baseline opioid level was 269.9 mg in the MP arm and 160.4 mg in the PL arm. At day-7 evaluation, there was no difference between the groups in pain intensity (MP, 3.60 v PL, 3.68; P =.88) or relative analgesic consumption (MP, 1.19 vPL, 1.20; P=.95). Clinically and statistically significant improvements were found in fatigue (-17 v 3 points; P.003), appetite loss (-24 v2 points; P=.003), and patient satisfaction (5.4 v2.0 points; P=.001) in favor of the MP compared with the PL group, respectively. There were no differences in adverse effects between the groups. Conclusion: MP 32 mg daily did not provide additional analgesia…(ver más)

Valora esta noticia

1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...